ATE229943T1 - Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen - Google Patents

Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen

Info

Publication number
ATE229943T1
ATE229943T1 AT98105754T AT98105754T ATE229943T1 AT E229943 T1 ATE229943 T1 AT E229943T1 AT 98105754 T AT98105754 T AT 98105754T AT 98105754 T AT98105754 T AT 98105754T AT E229943 T1 ATE229943 T1 AT E229943T1
Authority
AT
Austria
Prior art keywords
substituted
imidazo
amines
quinoline
production
Prior art date
Application number
AT98105754T
Other languages
English (en)
Inventor
John F Gerster
Stephen L Crooks
Kyle J Lindstrom
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Application granted granted Critical
Publication of ATE229943T1 publication Critical patent/ATE229943T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lubricants (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
AT98105754T 1991-03-01 1992-02-20 Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen ATE229943T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66292691A 1991-03-01 1991-03-01
US68732691A 1991-04-18 1991-04-18

Publications (1)

Publication Number Publication Date
ATE229943T1 true ATE229943T1 (de) 2003-01-15

Family

ID=27098631

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98105754T ATE229943T1 (de) 1991-03-01 1992-02-20 Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen
AT92906763T ATE179711T1 (de) 1991-03-01 1992-02-20 1,2-substituierte 1h-imidazo(4,5-c>chinolin-4- amine

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT92906763T ATE179711T1 (de) 1991-03-01 1992-02-20 1,2-substituierte 1h-imidazo(4,5-c>chinolin-4- amine

Country Status (18)

Country Link
EP (2) EP0872478B1 (de)
JP (1) JP2955019B2 (de)
AT (2) ATE229943T1 (de)
AU (2) AU658621B2 (de)
CA (2) CA2104782C (de)
CZ (1) CZ285050B6 (de)
DE (2) DE69229114T2 (de)
DK (2) DK0872478T3 (de)
ES (2) ES2131070T3 (de)
HU (5) HU222111B1 (de)
IE (1) IE920605A1 (de)
IL (2) IL101110A (de)
NO (1) NO303729B1 (de)
NZ (1) NZ241784A (de)
PH (1) PH31614A (de)
SG (2) SG46492A1 (de)
UA (1) UA32546C2 (de)
WO (1) WO1992015582A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
CZ288182B6 (en) * 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US6133547A (en) * 1996-09-05 2000-10-17 Medtronic, Inc. Distributed activator for a two-dimensional shape memory alloy
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JPH10298181A (ja) * 1997-04-25 1998-11-10 Sumitomo Pharmaceut Co Ltd タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤
UA75622C2 (en) * 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
EP1541572A1 (de) * 2000-12-08 2005-06-15 3M Innovative Properties Company Thioether substituierte Imidazochinoline
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
DK1543002T3 (da) * 2002-07-23 2006-12-27 Teva Gyogyszergyar Zartkoeruee Fremstilling af 1H-imidazo (4,5-c) quinolin-4-aminer via 1H-imidazo (4,5-c) quinolin-4-phtalimid mellemprodukter
RU2412942C2 (ru) 2003-10-03 2011-02-27 3М Инновейтив Пропертиз Компани Оксизамещенные имидазохинолины, способные модулировать биосинтез цитокинов
MY161812A (en) 2003-11-25 2017-05-15 3M Innovative Properties Co Substituted imidazo ring systems and methods
US7884207B2 (en) * 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
CN101180312A (zh) 2005-02-18 2008-05-14 诺华疫苗和诊断公司 来自尿路病原性大肠杆菌的免疫原
CA2598695A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
CA2598437A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
WO2006091567A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
EP1863814A1 (de) 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. 1-substitutierte pyrazolo-(3,4-c)-ringverbindungen als cytokinbiosynthese-modulatoren für die behandlung viraler infektionen und neoplastischer erkrankungen
NZ567978A (en) 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP2368572B1 (de) 2005-11-04 2020-03-04 Seqirus UK Limited Adjuvansimpfstoffe mit nicht virenähnlichen Antigenen aus Influenza-Viren, die in einer Zellkultur gezüchtet wurden
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
CA2628131C (en) * 2005-11-04 2012-03-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
EP1951298A1 (de) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Grippeimpfstoffe mit adjuvantien und zytokin-induzierenden mitteln
PT2478916T (pt) 2006-01-27 2020-07-03 Seqirus Uk Ltd Vacinas de influenza que contêm hemaglutinina e proteínas da matriz
EP2382987A1 (de) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Lagerung von Influenza-Impfstoffen ohne Kühlung
SG173336A1 (en) 2006-03-31 2011-08-29 Novartis Ag Combined mucosal and parenteral immunization against hiv
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US8124096B2 (en) 2006-07-31 2012-02-28 3M Innovative Properties Company Immune response modifier compositions and methods
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
EP3456348A1 (de) 2006-09-11 2019-03-20 Seqirus UK Limited Herstellung von influenza-virus-impfstoffen ohne verwendung von eiern
ES2480491T3 (es) 2006-12-06 2014-07-28 Novartis Ag Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
JP5400763B2 (ja) * 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
EP2484377A1 (de) 2007-06-27 2012-08-08 Novartis AG Influenza Impfstoffe mit wenig Zusatzstoffen
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
NZ588191A (en) * 2008-03-03 2012-06-29 Irm Llc Compounds and compositions as tlr activity modulators
KR20100135766A (ko) 2008-03-18 2010-12-27 노파르티스 아게 인플루엔자 바이러스 백신 항원 제조의 개선
NZ599446A (en) * 2008-03-24 2013-11-29 4Sc Discovery Gmbh Novel substituted imidazoquinolines
EP2403526B1 (de) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia-antigene
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
KR20120027276A (ko) 2009-04-27 2012-03-21 노파르티스 아게 인플루엔자를 예방하기 위한 면역증강된 백신
AU2010269961A1 (en) 2009-07-07 2012-02-02 Novartis Ag Conserved Escherichia coli immunogens
HRP20220756T1 (hr) 2009-07-15 2022-09-02 Glaxosmithkline Biologicals S.A. Proteinski pripravci rsv f i postupci za izradu istih
DK2464658T3 (en) 2009-07-16 2014-12-15 Novartis Ag Detoxified escherichia coli immunogens
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011084725A1 (en) * 2009-12-21 2011-07-14 3M Innovative Properties Company 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
WO2011084726A1 (en) * 2009-12-21 2011-07-14 3M Innovative Properties Company BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
KR20130108983A (ko) 2010-05-26 2013-10-07 셀렉타 바이오사이언시즈, 인크. 커플링되지 않은 애주번트를 갖는 나노담체 조성물
WO2011151723A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
AU2011262312B2 (en) 2010-06-01 2015-05-28 Novartis Ag Concentration and lyophilization of influenza vaccine antigens
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
ES2531577T3 (es) 2010-08-20 2015-03-17 Novartis Ag Conjuntos de agujas para la administración de vacuna soluble contra la gripe
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
EP4159232A1 (de) 2011-01-26 2023-04-05 GlaxoSmithKline Biologicals S.A. Rsv-immunisierungstherapie
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
US9149541B2 (en) 2011-07-08 2015-10-06 Novartis Ag Tyrosine ligation process
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
MX2015004171A (es) 2012-10-02 2015-10-22 Glaxosmithkline Biolog Sa Conjugados de sacaridos no lineales.
ES2826555T3 (es) 2012-11-30 2021-05-18 Glaxosmithkline Biologicals Sa Antígenos de Pseudomonas y combinación de antígenos
RU2721418C2 (ru) * 2013-02-01 2020-05-19 Веллстат Терапьютикс Корпорейшн Соединения амина, имеющие противовоспалительную, противогрибковую, противопаразитарную и противораковую активность
EP2870974A1 (de) 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
SI3122378T1 (sl) 2014-03-26 2020-03-31 Glaxosmithkline Biologicals S.A. Mutantni stafilokokni antigeni
EP3134402B1 (de) 2014-04-22 2020-05-06 F.Hoffmann-La Roche Ag 4-amino-imidazochinolin-verbindungen
MA41625A (fr) 2015-03-06 2018-01-10 Hoffmann La Roche Composés de benzazépine dicarboxamide
WO2017046675A1 (en) * 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
JP6893501B2 (ja) 2015-09-17 2021-06-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト スルフィニルフェニル又はスルホンイミドイルフェニルベンザゼピン
EP3464245B1 (de) 2016-05-23 2020-10-14 H. Hoffnabb-La Roche Ag Benzazepindicarboxamidverbindungen mit tertiärer amidfunktion
EP3464274B1 (de) 2016-05-23 2020-05-27 H. Hoffnabb-La Roche Ag Benzazepindicarboxamidverbindungen mit sekundärer amidfunktion
CN109311851B (zh) 2016-06-12 2021-08-10 豪夫迈·罗氏有限公司 二氢嘧啶基苯并氮杂䓬甲酰胺化合物
TWI674261B (zh) * 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
DK3625231T3 (da) * 2017-05-19 2022-10-31 Superb Wisdom Ltd Derivatives of resiquimod
MX2019015744A (es) * 2017-06-23 2020-02-20 Birdie Biopharmaceuticals Inc Composiciones farmaceuticas.
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
DK0385630T3 (da) * 1989-02-27 1997-05-12 Riker Laboratories Inc 1H-imidazo(4,5-c)quinolin-4-aminer som antivirale midler

Also Published As

Publication number Publication date
AU1566992A (en) 1992-10-06
NZ241784A (en) 1995-06-27
HU211242A9 (en) 1995-11-28
IL114570A (en) 1996-10-31
IE920605A1 (en) 1992-09-09
IE990988A1 (en) 2000-12-13
IL114570A0 (en) 1995-11-27
ATE179711T1 (de) 1999-05-15
CA2104782C (en) 2001-08-07
DK0582581T3 (da) 1999-11-08
PH31614A (en) 1999-01-12
UA32546C2 (uk) 2001-02-15
AU2715795A (en) 1995-09-21
NO933069L (no) 1993-11-01
NO303729B1 (no) 1998-08-24
CA2289219A1 (en) 1992-09-02
JPH06504789A (ja) 1994-06-02
NO933069D0 (no) 1993-08-27
HU9701084D0 (en) 1997-08-28
EP0582581A1 (de) 1994-02-16
AU673309B2 (en) 1996-10-31
EP0872478B1 (de) 2002-12-18
WO1992015582A1 (en) 1992-09-17
SG70625A1 (en) 2000-02-22
EP0872478A3 (de) 1998-11-04
ES2131070T3 (es) 1999-07-16
DE69232878T2 (de) 2003-11-20
IL101110A (en) 1995-12-08
SG46492A1 (en) 1998-02-20
HU222251B1 (hu) 2003-05-28
DK0872478T3 (da) 2003-03-31
EP0872478A2 (de) 1998-10-21
ES2186034T3 (es) 2003-05-01
DE69232878D1 (de) 2003-01-30
JP2955019B2 (ja) 1999-10-04
HU222247B1 (hu) 2003-05-28
CA2289219C (en) 2003-05-20
HU222250B1 (hu) 2003-05-28
HU9701089D0 (en) 1997-08-28
CA2104782A1 (en) 1992-09-02
HU222111B1 (hu) 2003-04-28
HUT67026A (en) 1995-01-30
EP0582581B1 (de) 1999-05-06
DE69229114D1 (de) 1999-06-10
CZ178893A3 (en) 1995-10-18
HU9302457D0 (en) 1993-11-29
AU658621B2 (en) 1995-04-27
HU9701083D0 (en) 1997-08-28
DE69229114T2 (de) 1999-11-04
IL101110A0 (en) 1992-11-15
CZ285050B6 (cs) 1999-05-12

Similar Documents

Publication Publication Date Title
ATE229943T1 (de) Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen
NO304946B1 (no) Xantinderivat samt dets anvendelse
FI822864A0 (fi) Karbapenem-derivat, foerfarande foer tillverkning av dessa och sammansaettningar innehaollande dessa
PT920430E (pt) Derivados de purina e sua utilizacao como anticoagulantes
CZ158295A3 (en) Substituted pyrazole per se and for treating diseases, pharmaceutical compositions based thereon and intermediates for their preparation
TW221814B (de)
AU6947401A (en) Phenylpyridazine derivatives and drugs containing the same
MY141488A (en) Hydroximic acid derivatives, processes for their preparation, and compositions comprising them
DK0579968T3 (da) 4-Iminoquinoliner, fremgangsmåde til deres fremstilling og deres anvendelse
ATE165815T1 (de) N-phenyl-2-cyano-3-hydroxypropenamide, ihre tautomeren, ihre salze, verfahren zu ihrer herstellung, ihre anwendung als medikamente und zusammensetzungen, die sie enthalten
EP0820997A4 (de) Pyrazol[1,5-a]pyrimidin derivate
EP0551844A3 (de)
ATE139767T1 (de) Verfahren zur herstellung 5-pyrazolomerkaptan- derivate und dessen zwischenprodukte
DE69218718D1 (de) Pharmazeutische Zusammensetzungen die Triazole Derivate enthalten zur rektalen Verabbrechung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0872478

Country of ref document: EP

REN Ceased due to non-payment of the annual fee